Developing an RNA vaccine to enhance the immune response against HIV
Official title: Engineering the Immune Response of a Self-replicating and Adjuvanting RNA HIV-1Vaccine
Funded at Hdt Bio Corporation · NIH-11084572 · Data updated 2026-11-12
This study is testing a new mRNA vaccine that aims to help your immune system fight HIV-1 by encouraging it to produce strong antibodies, using a special delivery method to make it work better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hdt Bio Corporation NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | April 9, 2021 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $981,683 |
| NIH project number | 5R33AI161811-05 |
| Project ID | NIH-11084572 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals at high risk for HIV infection, particularly those who are unvaccinated and between the ages of 0-11.
✕Less likely to help
Patients who are already HIV-positive or those with severe immunocompromising conditions may not benefit from this research.
What this research studies
This research focuses on creating a messenger RNA (mRNA) vaccine designed to stimulate the immune system to produce broadly neutralizing antibodies against HIV-1. The vaccine utilizes a novel delivery system involving lipid inorganic nanoparticles to enhance its effectiveness. By optimizing the formulation and administration of this vaccine, the researchers aim to improve B cell differentiation and antibody production, which are crucial for effective immunity. The project builds on previous successes with mRNA vaccines and aims to advance the development of a viable HIV vaccine.
Why it matters
Potential benefit: If successful, this research could lead to a more effective vaccine against HIV, potentially reducing the incidence of HIV infections.
How similar studies have gone: Previous research with mRNA vaccines has shown promising results, indicating that this approach has the potential for success in developing an effective HIV vaccine.
Where this research is happening
-
Hdt Bio Corporation
Seattle, United States Active
Researchers
- Principal investigator: Khandhar, Amit Praful — Hdt Bio Corporation
- Study coordinator: Khandhar, Amit Praful
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.